See more : Nichols plc (NJMVF) Income Statement Analysis – Financial Results
Complete financial analysis of Trillium Therapeutics Inc. (TRIL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Trillium Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Pricer AB (publ) (0H38.L) Income Statement Analysis – Financial Results
- IJM Corporation Berhad (3336.KL) Income Statement Analysis – Financial Results
- Rémy Cointreau SA (REMYF) Income Statement Analysis – Financial Results
- Crawford United Corporation (CRAWA) Income Statement Analysis – Financial Results
- Great Portland Estates Plc (GPOR.L) Income Statement Analysis – Financial Results
Trillium Therapeutics Inc. (TRIL)
About Trillium Therapeutics Inc.
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 148.00K | 124.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 147.85K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 148.00 | 124.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.10% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 25.35M | 25.30M | 31.88M | 29.53M | 22.16M | 13.01M | 9.13M | 3.13M | 626.79K | 818.29K | 1.76M | 2.26M | 2.22M | 1.87M | 1.85M | 888.00K | 171.39K |
| General & Administrative | 36.26M | 4.31M | 2.63M | 3.07M | 2.93M | 2.29M | 2.22M | 903.67K | 468.71K | 1.41M | 2.44M | 1.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 36.26M | 4.31M | 2.63M | 3.07M | 2.93M | 2.29M | 2.22M | 903.67K | 468.71K | 1.41M | 2.44M | 1.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 3.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 902.08K | 269.33K | 287.57K | 2.41M | 3.52M | -6.01M | 1.78M | 559.18K |
| Operating Expenses | 61.60M | 32.61M | 34.51M | 32.60M | 25.09M | 15.30M | 11.35M | 4.04M | 1.10M | 3.13M | 4.47M | 4.47M | 4.63M | 5.38M | -4.16M | 2.67M | 730.58K |
| Cost & Expenses | 61.60M | 35.56M | 34.51M | 32.60M | 25.09M | 15.30M | 11.35M | 4.04M | 1.10M | 3.13M | 4.47M | 4.47M | 4.63M | 5.38M | -4.16M | 2.67M | 730.58K |
| Interest Income | 2.01M | 614.00K | 795.87K | 574.16K | 310.63K | 352.01K | 326.22K | 41.43K | 25.87K | 35.66K | 8.06K | 18.85K | 191.64K | 0.00 | 85.68K | 136.08K | 0.00 |
| Interest Expense | 0.00 | 177.00K | 31.57K | 54.08K | 48.63K | 52.89K | 60.10K | 37.69K | 0.00 | 14.03K | 0.00 | 0.00 | 133.84K | 0.00 | 284.56K | 307.87K | 0.00 |
| Depreciation & Amortization | 591.00K | 2.11M | 2.31M | 3.74M | 3.19M | 329.86K | 566.81K | 609.32K | 6.42K | 250.35K | 258.05K | 257.54K | 227.09K | 285.51K | 246.01K | 235.71K | 53.07K |
| EBITDA | -58.65M | -39.31M | -28.85M | -32.05M | -23.11M | -10.23M | -10.47M | -3.38M | -1.06M | -2.84M | -4.20M | -4.19M | -4.21M | -5.22M | -3.55M | -2.27M | -737.08K |
| EBITDA Ratio | -39,630.41% | -31,702.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -61.46M | -35.44M | -34.51M | -32.60M | -25.09M | -15.30M | -11.35M | -4.04M | -1.10M | -3.13M | -4.47M | -4.47M | -4.63M | -5.38M | 4.16M | -2.67M | -730.58K |
| Operating Income Ratio | -41,523.65% | -28,579.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.21M | -6.16M | 3.33M | -3.25M | -1.26M | 4.69M | 251.06K | 9.01K | 28.48K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -59.24M | -41.59M | -31.19M | -35.85M | -26.35M | -10.61M | -11.10M | -4.03M | -1.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -40,029.73% | -33,543.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 102.00K | 28.00K | 5.87K | 3.18K | -2.74M | 6.85K | 311.16K | 46.71K | 28.48K | 14.03K | 0.00 | 0.00 | 133.84K | 0.00 | 284.56K | 307.87K | 0.00 |
| Net Income | -59.35M | -41.62M | -31.19M | -35.86M | -23.61M | -10.62M | -11.10M | -4.03M | -1.07M | -3.11M | -4.46M | -4.45M | -4.57M | -5.51M | -4.08M | -2.82M | -790.15K |
| Net Income Ratio | -40,098.65% | -33,566.13% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.71 | -1.65 | -2.24 | -3.67 | -3.02 | -1.60 | -2.64 | -2.97 | -17.15 | -5.11 | -8.53 | -9.76 | -12.41 | -23.10 | -23.16 | -15.50 | -0.01 |
| EPS Diluted | -0.71 | -1.65 | -2.24 | -3.67 | -3.02 | -1.60 | -2.64 | -2.97 | -17.15 | -5.11 | -8.53 | -9.76 | -12.41 | -23.10 | -20.36 | -14.13 | -0.01 |
| Weighted Avg Shares Out | 83.75M | 25.26M | 13.91M | 9.77M | 7.82M | 6.64M | 4.20M | 1.36M | 62.21K | 608.26K | 522.68K | 455.62K | 368.01K | 238.38K | 176.29K | 181.67K | 105.00M |
| Weighted Avg Shares Out (Dil) | 83.75M | 25.26M | 13.91M | 9.77M | 7.82M | 6.64M | 4.20M | 1.36M | 62.21K | 608.26K | 522.68K | 455.62K | 368.01K | 238.38K | 200.54K | 199.29K | 105.00M |
TRIL Stock: The Huge $2.3B Deal Sending Trillium Therapeutics Up 200%
TRIL stock is soaring to nearly triple its Friday prices. Pfizer is acquiring the oncology company in a multi-billion dollar deal.
Pfizer to buy cancer drug maker Trillium for $2.3B
Pfizer said it will pay $18.50 a share for the Cambridge, Massachusetts-based drug maker Trillium.
Why Trillium Therapeutics Stock Is Skyrocketing Today
Pfizer may have gotten a fantastic deal on this clinical-stage oncology company.
Trillium Therapeutics Shares Increase Over 190% Pre-Market: Why It Happened
The shares of Trillium Therapeutics Inc (NASDAQ: TRIL) increased by over 190% pre-market. This is why it happened.
Trillium Therapeutics shares soar on Pfizer's $2.26B deal
Pfizer's $2.26B Trillium deal will target drugs for blood cancers, such as leukemia, multiple myeloma and lymphoma, according to the companies.
Trillium Therapeutics' stock nearly triples after buyout deal with Pfizer valued at $2.26 billion
Shares of Trillium Therapeutics Inc. TRIL, +3.92% nearly tripled in premarket trading Monday, skyrocketing 189.3%, after the immuno-oncology company announced an agreement to be acquired by Pfizer Inc. PFE, -0.16% in a cash deal valued $2.26 billion. Under terms of...
Pfizer to Acquire Trillium Therapeutics Inc.
Proposed acquisition strengthens Pfizer's category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies
Trillium Therapeutics Reports Second Quarter 2021 Operating and Financial Results
CAMBRIDGE, Mass., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three and six months ended June 30, 2021....
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine in TP53-Mutated Acute Myeloid Leukemia
CAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first TP53-mutated acute myeloid leukemia (AML) patient...
This Biotech Stock Is Too Cheap to Ignore
Wall Street's short attention span has created an attractive entry point in this once-loved biotech.
Source: https://incomestatements.info
Category: Stock Reports